Just - Evotec Biologics
Jason Friedman is a Senior Scientist at Just - Evotec Biologics, overseeing a team focused on early-phase upstream development and technology initiatives for continuous purification platforms since May 2023. Prior experience includes serving as the upstream lead for AAV viral vector platform development at Bristol Myers Squibb, where Jason facilitated process transfers from January 2021 to May 2023. Jason's background also comprises roles at AGC Biologics in upstream process development for CHO-derived therapeutics and research technician responsibilities at The Research Corporation of the University of Hawai'i, enhancing skills in data analysis and fieldwork. Academically, Jason holds an M.S. in Biological Oceanography from the University of Hawaii at Manoa and a B.S. in Biological Sciences from Cornell University.
Just - Evotec Biologics
1 followers
Just – Evotec Biologics, wholly owned by Evotec SE, is a first-to-industry biologics platform that leverages AI/ML technologies and world-leading molecular design, cell line development, process intensification and continuous manufacturing strategies to advance biotherapeutics from discovery through clinical stages to commercial launch. The Just – Evotec Biologics team combines deep industry experience in the fields of data, protein, process, and manufacturing sciences including automation with highly integrated and flexible capabilities to break through the scientific and economic barriers associated with the development of protein therapeutics. Our focus is to accelerate and expand access to biotherapeutics through scientific and technological innovation for our proprietary projects and on behalf of our partners. Learn more at www.just-evotecbiologics.com